ArticleCancer medicine2026
Histone 3 Hyperacetylation and the Aggressive Behavior of Giant Cell Lesions.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionGiant Cell Lesions exhibit variable aggressive clinical behavior. Understanding the molecular mechanisms of these lesions can facilitate a more personalized and effective therapeutic approach. MATERIAL AND
methodsThe acetylation of Histone H3 at Lysine 9 (H3K9ac) and the expression of Inhibitor of Growth Protein 5 (ING5) were evaluated in 19 cases of Peripheral Giant Cell Granuloma (PGCG), 19 cases of non-aggressive Central Giant Cell Granuloma (CGCG), 19 cases of aggressive CGCG, and 19 cases of Giant Cell Tumor of Bone (GCTB), totaling 76 cases of Giant Cell Lesions.
resultsH3K9 hyperacetylation was found in aggressive Giant Cell Lesions compared to non-aggressive lesions (p < 0.05). Aggressive Giant Cell Lesions also show higher ING5 expression in multinucleated giant cells and cannibalistic multinucleated giant cells compared to non-aggressive lesions (p < 0.05). There was no difference in the levels of H3K9ac and ING5 between aggressive Central Giant Cell Granuloma and Giant Cell Tumor of Bone (p > 0.05). H3K9ac and ING5 were associated with aggressive characteristics in the CGCG (p < 0.05).
conclusionH3K9 hyperacetylation highlights the significance of this epigenetic event in the aggressiveness of Giant Cell Lesions and may indicate their potential for aggressive behavior, thereby providing information to improve treatment strategies, particularly for Central Giant Cell Granuloma. Understanding the CGCG's clinical behavior is essential for determining the therapeutic modality and avoiding long-term post-treatment sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.